The effect of human growth hormone therapy on GH binding protein in GH-deficient children.
Previous studies have described the close similarity of the GH binding protein to the liver membrane GH receptor. Since GH regulates its own liver receptors, we examined the effects of short- and long-term hGH therapy on GH binding protein in children with GH deficiency. Six GH-deficient children received their first hGH dose ever, and the pharmacodynamics of serum GH was followed for 12 h, along with measurements of GH binding protein activity. Over the first 6 h, serum GH and GH binding protein activity exhibited a parallel increase, followed by gradual decrease. At 8 h, some of the patients exhibited an apparent second peak in GH binding protein, despite the continuous decrease in serum hGH. During the period of hGH treatment, serum GH binding protein increased progressively over a period of 6 months. In a second uncontrolled group of 7 GH-deficient patients who had been treated with hGH for 30-36 months, GH binding protein activity was also significantly higher than pretreatment values. We suggest that the short-term pharmacodynamic changes probably represent the endogenous turnover of the GH receptor, whereas the elevated GH binding protein activity on hGH treatment may reflect up-regulation of the GH receptor.
Hochberg
Z
Z
Rappaport Family Institute for Research in The Medical Science, Technion, Haifa, Israel.
Barkey
R J
RJ
Even
L
L
Peleg
I
I
Youdim
M B
MB
Amit
T
T
D001827:Body Height; D002352:Carrier Proteins / Q000378:metabolism*; D002648:Child; D013006:Growth Hormone / Q000172:deficiency* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D008661:Metabolism, Inborn Errors / Q000188:drug therapy*; D012016:Reference Values; D013997:Time Factors
D002352:Carrier Proteins; D013006:Growth Hormone; C051815:somatotropin-binding protein